Skip to main content
SpringerLink
Log in

Blood pressure control rates with an antihypertensive regimen including trandolapril in a canadian usual-care setting

  • Original Research
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Introduction

The aim of the study was to assess the effects on blood pressure (BP) levels and control rates in hypertensive subjects receiving trandolapril as monotherapy or as part of an antihypertensive regimen in everyday Canadian clinical practice.

Methods

The MAVIKtory study was a multicenter, single-arm observational study in 601 primary-care centers in Canada. Diabetic and nondiabetic subjects were included, who were treated with trandolapril for hypertension in accordance with usual practices and national guidelines. Subjects received trandolapril as a new prescription, alone, or in combination with prior therapy. Treatment regimens were at the discretions of the treating physicians. Subjects were followed for 6 months. The primary outcomes measures were the percentage of subjects reaching BP targets set by their physicians after 6 months of therapy, and the percentage of subjects reaching the guidelines targets (systolic blood pressure [SBP]/diastolic blood pressure [DBP] <140/90 mm Hg) after 6 months as assessed by their physicians. Other outcomes were the percentage of diabetic subjects reaching BP targets, and tolerability.

Results

A total of 8787 subjects were enrolled and included in the intention-to-treat population. Starting doses of trandolapril were 1 or 2 mg in the majority of subjects and remained unchanged in 51.9% of the population at 6 months. The target of <140/90 (<130/80) mm Hg was reached by 67.3% of the population. The lower mean physician-set target of 133.4/83.3 mm Hg for nondiabetic subjects and 128.6/79.3 mm Hg for diabetic subjects was reached by 52.2%. Mean reductions from baseline to month 6 were 19.4 mm Hg (95% CI: [−19.9 to −19.0]) in SBP, and 10.1 mm Hg (95% CI: [−10.4 to −9.8]) in DBP. Cough was the most commonly reported adverse event, reported in 4.2% of all subjects.

Conclusion

Trandolapril demonstrated a favorable safety and effectiveness profile. SBP reductions of approximately 20 mm Hg and control rates >65% could be achieved over 6 months.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Berenson GS, Srinivasan SR, Bao W, Newman WP III, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med. 1998;338:1650–1656.

    Article  PubMed  CAS  Google Scholar 

  2. Thompson DW, Furlan AJ. Clinical epidemiology of stroke. Neurol Clin. 1996;14:309–315.

    Article  PubMed  CAS  Google Scholar 

  3. World Health Organisation. The world health report 2002. Reducing risks, promoting healthy life. Geneva: The World Health Organisation; 2002.

    Google Scholar 

  4. Murray CJ, Lopez AD. Evidence based health policy - lessons from the Global Burden of Disease Study. Science. 1996;274:740–743.

    Article  PubMed  CAS  Google Scholar 

  5. Murray CJ, Lopez AD. Global mortality, disability and the contribution of risk factors: Global Burden of Disease Study. Lancet. 1997;349:1436–1446.

    Article  PubMed  CAS  Google Scholar 

  6. Joffres MR, Hamet P, MacLean DR, L’italien GJ, Fodor G. Distribution of blood pressure and hypertension in Canada and the United States. Am J Hypertens. 2001;14:1099–1105.

    Article  PubMed  CAS  Google Scholar 

  7. Califf RM. A virtuous cycle to improve hypertension outcomes at a national level: linking public health and individualized medicine. Hypertension. 2009;53:105–107.

    Article  PubMed  CAS  Google Scholar 

  8. Campbell NR, Brant R, Johansen H, et al. Canadian Hypertension Education Program Outcomes Research Task Force. Increases in antihypertensive prescriptions and reductions in cardiovascular events in Canada. Hypertension. 2009;53:128–134.

    Article  PubMed  CAS  Google Scholar 

  9. Campbell NR, So L, Amankwah E, Quan H, Maxwell C. Canadian Hypertension Education Program Outcomes Research Task Force. Characteristics of hypertensive Canadians not receiving drug therapy. Can J Cardiol. 2008;24:485–490.

    Article  PubMed  Google Scholar 

  10. Petrella RJ, Campbell NRC. Awareness and misconception of hypertension in Canada: Results of a national survey. Can J Cardiol. 2005;21:589–593.

    PubMed  Google Scholar 

  11. The 2010 Canadian Hypertension Education Program Recommendations (CHEP). Available at: http://hypertension.ca/chep/wp-content/uploads/2010/04/FullRecommendations2010.pdf. Accessed June 10, 2011.

  12. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417–2428.

    Article  PubMed  CAS  Google Scholar 

  13. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs - do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med. 1995;332:1125–1131.

    Article  PubMed  CAS  Google Scholar 

  14. Cardinal H, Monfared AA, Dorais M, Lelorier J. A comparison between persistence to therapy in ALLHAT and in everyday clinical practice: a generalizability issue. Can J Cardiol. 2004;20:417–421.

    PubMed  Google Scholar 

  15. Guay DR. Trandolapril: a newer angiotensin-converting enzyme inhibitor. Clin Ther. 2003;25:713–715.

    Article  PubMed  CAS  Google Scholar 

  16. Tytus R, Burgess E, Assouline L, Vanjaka A. A 26-week, prospective, open-label, uncontrolled, multicenter study to evaluate the effect of an escalating-dose regimen of trandolapril on change in blood pressure in treatment-naive and concurrently treated adult hypertensive subjects (TRAIL). Clin Ther. 2007;29:305–315.

    Article  PubMed  CAS  Google Scholar 

  17. Tytus RH, Burgess ED, Assouline L, Vanjaka A. Effectiveness of a trandolapril-based treatment regimen in subjects with isolated systolic hypertension in Canada. Curr Med Res Opin. 2009;25:1379–1384.

    Article  PubMed  CAS  Google Scholar 

  18. Biswas PN, Wilton LV, Shakir SW. The safety of valsartan: results of a postmarketing surveillance study on 12 881 patients in England. J Hum Hypertens. 2002;16:795–803.

    Article  PubMed  CAS  Google Scholar 

  19. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ. 1996;312:1215–1218.

    PubMed  CAS  Google Scholar 

  20. Greener M. Drug safety on trial. EMBO Rep. 2005;6:202–204.

    Article  PubMed  CAS  Google Scholar 

  21. Baker WL, Coleman CI, Kluger J, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease. Ann Intern Med. 2009;151:861–871.

    PubMed  Google Scholar 

  22. Bent S, Padula A, Avins AL. Better ways to question patients about adverse medical events: a randomized, controlled trial. Ann Intern Med. 2006;144:257–261.

    PubMed  Google Scholar 

  23. Matchar DB, McCrory DS, Orlando LA, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med. 2008;148:16–29.

    PubMed  Google Scholar 

  24. Stergiou, G. DEMANT. Data presented at the European Society of Hypertension annual meeting. Milan, Italy, June 29th, 2011.

  25. Lachaine J, Petrella RJ, Merikle E, Ali F. Choices, persistence and adherence to antihypertensive agents: evidence from RAMQ data. Can J Cardiol. 2008;24:269–273.

    Article  PubMed  Google Scholar 

  26. Jones JK, Gorkin L, Lian JF, Staffa JA, Fletcher AP. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. BMJ. 1995;311:293–295.

    PubMed  CAS  Google Scholar 

  27. Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ. 1999;160:41–46.

    PubMed  CAS  Google Scholar 

  28. Burnier M, Hess B, Greminger P, Waeber B. Determinants of persistence in hypertensive patients treated with irbesartan: results of a postmarketing survey. BMC Cardiovasc Disord. 2005;5:13.

    Article  PubMed  Google Scholar 

  29. Marentette MA, Gerth WC, Billings DK, Zarnke KB. Antihypertensive persistence and drug class. Can J Cardiol. 2002;18:649–656.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hamilton Health Sciences, Hamilton, ON, Canada

    Richard H. Tytus

  2. McMaster University, 1280 Main Street West, Hamilton, ON, L8S4L8, Canada

    Richard H. Tytus

  3. Abbott Laboratories, Montreal, QC, Canada

    Linda Assouline & Anita Vanjaka

Authors
  1. Richard H. Tytus
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Linda Assouline
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anita Vanjaka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard H. Tytus.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tytus, R.H., Assouline, L. & Vanjaka, A. Blood pressure control rates with an antihypertensive regimen including trandolapril in a canadian usual-care setting. Adv Therapy 28, 789–798 (2011). https://doi.org/10.1007/s12325-011-0053-x

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-011-0053-x

Keywords

Search

Navigation